Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

Table 5 Combined analysis of G1m status according to change in DAS28 and to the EULAR criteria

Strata	G1m genotype ^a	number	Baseline DAS28	ΔDAS28	Beta ^b	*P-value* ^b	R ^c	NR ^c	OR ^b	*P-value* ^b
All patients	G1m1,17+	523	6.3 ± 1.1	2.3 ± 1.4	0.09	0.002	153 (29.3)	79 (15.1)	1.5	0.035
	G1m1,17-	429	6.2 ± 1.2	2.0 ± 1.5			98 (22.8)	90 (21.0)
INX	G1m1,17+	387	6.3 ± 1.1	2.3 ± 1.5	0.11	0.001	116 (30.0)	67 (17.3)	1.5	0.03
	G1m1,17-	314	6.2 ± 1.3	1.9 ± 1.5			67 (21.3)	78 (24.8)
ADM	G1m1,17+	136	6.2 ± 1.1	2.5 ± 1.4	0.03	0.55	37 (27.2)	12 (8.8)	1.1	0.57
	G1m1,17-	115	6.2 ± 1.2	2.5 ± 1.4			31 (27.0)	12 (10.4)

^aCarrier status; ^banalyses adjusted for baseline DAS28 and gender (and anti-TNF for All patients); ^cnumber (% response class/all patients with this genotype). ADM, adalimumab; DAS28, disease activity score in 28 joints; IFX, infliximab; NR, non-responders; R, responders.

ISSN: 1478-6362